A pharmacoepidemiological study of Rivaroxaban use and potential adverse outcomes in routine clinical pratice in the United KingdomFirst published 14/10/2015 Last updated 23/04/2024 EU PAS number: EUPAS11299StudyFinalisedDownload as PDF
Fundación Centro Español de Investigación Farmacoepidemiológica (CEIFE)Spain First published: 15/03/2010Last updated 15/02/2024 InstitutionNot-for-profitENCePP partner